65 related articles for article (PubMed ID: 20153751)
1. The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats.
Ruggieri V; Vitale G; Filaferro M; Frigeri C; Pini LA; Sandrini M
Life Sci; 2010 Mar; 86(13-14):510-7. PubMed ID: 20153751
[TBL] [Abstract][Full Text] [Related]
2. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
3. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids modulate ultrasound-induced aversive responses in rats.
Finn DP; Jhaveri MD; Beckett SR; Kendall DA; Marsden CA; Chapman V
Psychopharmacology (Berl); 2004 Feb; 172(1):41-51. PubMed ID: 14634713
[TBL] [Abstract][Full Text] [Related]
5. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors.
Ottani A; Leone S; Sandrini M; Ferrari A; Bertolini A
Eur J Pharmacol; 2006 Feb; 531(1-3):280-1. PubMed ID: 16438952
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
8. The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats.
Roche M; O'Connor E; Diskin C; Finn DP
Eur J Neurosci; 2007 Nov; 26(9):2643-53. PubMed ID: 17970731
[TBL] [Abstract][Full Text] [Related]
9. Serotonin and opiate involvement in the antinociceptive effect of acetylsalicylic acid.
Pini LA; Vitale G; Sandrini M
Pharmacology; 1997 Feb; 54(2):84-91. PubMed ID: 9088041
[TBL] [Abstract][Full Text] [Related]
10. Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat.
Pini LA; Sandrini M; Vitale G
Inflamm Res; 1995 Jan; 44(1):30-5. PubMed ID: 7664027
[TBL] [Abstract][Full Text] [Related]
11. Significance of cannabinoid CB1 receptors in improgan antinociception.
Gehani NC; Nalwalk JW; Razdan RK; Martin BR; Sun X; Wentland M; Abood ME; Hough LB
J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043
[TBL] [Abstract][Full Text] [Related]
12. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
Scott DA; Wright CE; Angus JA
Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
[TBL] [Abstract][Full Text] [Related]
13. Acetylsalicylic acid potentiates the antinociceptive effect of morphine in the rat: involvement of the central serotonergic system.
Sandrini M; Ottani A; Vitale G; Pini LA
Eur J Pharmacol; 1998 Aug; 355(2-3):133-40. PubMed ID: 9760027
[TBL] [Abstract][Full Text] [Related]
14. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
[TBL] [Abstract][Full Text] [Related]
15. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
16. The influence of ACEA--a selective cannabinoid CB1 receptor agonist on whole blood and platelet-poor plasma serotonin concentrations.
Rutkowska M; Gliniak H
Pharmazie; 2009 Sep; 64(9):598-601. PubMed ID: 19827303
[TBL] [Abstract][Full Text] [Related]
17. The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats.
Robinson L; Goonawardena AV; Pertwee RG; Hampson RE; Riedel G
Br J Pharmacol; 2007 Jul; 151(5):688-700. PubMed ID: 17502849
[TBL] [Abstract][Full Text] [Related]
18. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
19. Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat.
Naderi N; Shafaghi B; Khodayar MJ; Zarindast MR
Eur J Pharmacol; 2005 May; 514(2-3):159-64. PubMed ID: 15910802
[TBL] [Abstract][Full Text] [Related]
20. Detection of cannabinoid agonist evoked increase in BOLD contrast in rats using functional magnetic resonance imaging.
Shah YB; Prior MJ; Dixon AL; Morris PG; Marsden CA
Neuropharmacology; 2004 Mar; 46(3):379-87. PubMed ID: 14975693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
